key: cord-1049833-v79rprdi
authors: Imam, Zaid; Odish, Fadi; Gill, Inayat; O'Connor, Daniel; Armstrong, Justin; Vanood, Aimen; Ibironke, Oluwatoyin; Hanna, Angy; Ranski, Alexandra; Halalau, Alexandra
title: Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID‐19 patients in Michigan, United States
date: 2020-06-04
journal: J Intern Med
DOI: 10.1111/joim.13119
sha: 564a60156c648a7d0c25e9f66fb23432c91ce3c1
doc_id: 1049833
cord_uid: v79rprdi

INTRODUCTION: Higher comorbidity and older age have been reported as correlates of poor outcomes in COVID‐19 patients worldwide, however US data is scarce. We evaluated mortality predictors of COVID‐19 in a large cohort of hospitalized patients in the US. DESIGN: Retrospective, multicenter cohort of inpatients diagnosed with COVID‐19 by RT‐PCR from March 1‐April 1,2020 was performed, and outcome data evaluated from March 1‐April 17, 2020. Measures included demographics, comorbidities, clinical presentation, laboratory values, and imaging on admission. Primary outcome was mortality. Secondary outcomes included length of stay, time to death, and development of acute kidney injury in the first 48‐hours. RESULTS: 1305 patients were hospitalized during the evaluation period. Mean age was 61.0±16.3, 53.8% were male and 66.1% African‐American. Mean BMI was 33.2±8.8 kg/m2. Median Charlson Comorbidity Index (CCI) was 2 (1‐4), 72.6% of patients had at least one comorbidity, with hypertension (56.2%) and diabetes mellitus (30.1%) being the most prevalent. ACE‐I/ARB use and NSAIDs use were widely prevalent (43.3% and 35.7% respectively). Mortality occurred in 200 (15.3%) of patients with median time of 10 (6‐14) days. Age >60 (aOR:1.93,95% CI:1.26‐2.94), and CCI>3 (aOR:2.71,95% CI:1.85‐3.97) were independently associated with mortality by multivariate analyses. NSAIDs and ACE‐I/ARB use had no significant effects on renal failure in the first 48 hours. CONCLUSION: Advanced age and an increasing number of comorbidities are independent predictors of in‐hospital mortality for COVID‐19 patients. NSAIDs and ACE‐I/ARB use prior to admission is not associated with renal failure or increased mortality.

A large case series in New York City reporting on COVID-19 patients, reported a Caucasian predominance, a median age of 63 years, hypertension as the leading comorbidity, and a high mortality rate of 21% 3 . We aimed to study patient demographics and their impact on in-hospital mortality in a large cohort of COVID-19 patients in southeast Michigan, USA with the hypothesis that older age and increasing comorbidity are predictors of in-hospital mortality.

Retrospective review of all inpatient records in Beaumont Health's eight hospitals was performed aiming to describe the epidemiologic and clinical characteristics of COVID-19 patients. Beaumont Health is the largest healthcare system in Southeast Michigan caring for over one third of patients in the Detroit Metropolitan area. Individuals were included if they were hospitalized with SARS-CoV-2 infection demonstrated by a positive RT-PCR on nasopharyngeal swab per world health organization (WHO) guidance 4 between March 1-April 1,2020.

Data was abstracted through automated reports generated through ToadDataPoint multi-platform database query tool from Beaumont's electronic medical record (EPIC System, Verona, WI, USA). Manual chart review was performed to confirm mortality to ensure accuracy and completeness. Variables abstracted included: demographics, comorbidities, clinical presentation, initial imaging findings, initial basic laboratory values, common medications, and outcomes. Comorbidities were computed into the Charlson Comorbidity Index (CCI), a well-validated index that predicts risk of death within 1 year of hospitalization 5 .

Primary outcome analyzed was mortality. Secondary outcomes included Non-invasive ventilation (NIV) requirement defined as a need for bi-level airway pressure (BiPAP) or high flow nasal cannula (HFNC) support during admission, length of stay, intensive care unit admission, mechanical ventilation requirement and duration. Acute kidney injury (AKI) was defined per the KDIGO criteria for serum creatinine elevation >0.3 mg/dl over 48 hours 6 .

Continuous data were reported as means and standard deviation (SD) or medians and interquartile range (IQR), and categorical variables as proportions. Logistic regression was used to evaluate univariate associations. Pertinent variables with P-values <0.20 were included in the multivariate logistic regression model. All P-values were from 2-sided tests and results were deemed statistically significant at P < 0.05. All statistical analyses were performed using International

Business Machines (IBM) Statistical Package for the Social Sciences (SPSS) 25, (IBM Corporation: Armonk, NY, 10504).

A total of 1305 patients were analyzed. Angiotensin converting enzyme inhibitor (ACE-I) and angiotensin receptor blocker (ARB) use prior to admission was reported in 565 patients (43.4%) and non-steroidal anti-inflammatory drugs (NSAIDs) use in 466 patients (35.7%). Table 2 summarizes the clinical presentation, initial imaging, and initial laboratory findings. Most common symptoms were cough (70.6%), fever (65.3%), and dyspnea (63.4%). Median cough duration was 5 (2-7) days before admission.

Other common symptoms include fatigue (36.1%), myalgias (22.6%), diarrhea (18.9%), and nausea (17.2%).

Most common findings on initial chest X-ray were bilateral infiltrates/opacities (54.9%) followed by no infiltrates/opacities (27.6%), and unilateral infiltrates/opacities (17.4%). Similarly, chest computed tomography (CT) showed bilateral infiltrates/opacities in 81.9% of patients, no infiltrates/opacities in 9.5%, and unilateral infiltrates/opacities (8.6%). 

This article is protected by copyright. All rights reserved Mortality did not differ significantly with sex, race, smoking history, BMI, type of infiltrates or absence of infiltrates on chest imaging, DM, heart failure, obstructive sleep apnea, asthma, chronic liver disease, dementia, immunosuppression, peptic ulcer disease, or connective tissue disease. ACE-I/ARB use was not associated with increased mortality on multivariate analysis.

Only initial serum creatinine was found to be an independent predictor of AKI (aOR:1.2, 95% CI:1.1-1.30). Age >60, sex, race, smoking history, BMI, DM, NSAID use and ACE-I/ARB use were not associated with an increased risk of AKI in the first 48 hours. CCI>3, HTN and CKD were associated with increased AKI risk on univariate analysis but were not significant on multivariate analysis (P=.200, P=.324, P=.357 respectively). These results are summarized in Table 3 .

In this large cohort of hospitalized COVID-19 patients, 66.1% were African-American, averaging 61 years of age, with a slight male predominance. The age and sex demographics appear similar to a 5700-patient cohort from NYC (63 years, 60.3% males), however only 22.6% of the latter cohort were African-American 3 . HTN was the most common comorbidity in our study followed by DM, and CKD. More than half of the cohort had at least one comorbidity, and an average BMI of 33.2 kg/m 2 . Comorbid pulmonary conditions were reported in less than 10% of the cohort. This could be due to underreporting or under-documentation in the electronic medical record. Overall, obese, older male patients with multiple comorbidities have been reported to have greater disease severity warranting hospitalization 3, 7 .

Thirty symptoms were evaluated on presentation and cough, dyspnea, fever, and fatigue were the most common; similar to other cohorts [8] [9] [10] . Diarrhea was the most common gastrointestinal manifestation in 18.9% of patients, and more common than other cohorts [10] [11] . In contrast to studies in Italy, lower ICU admission and mechanical ventilation rates were noted in our cohort despite similar age, demographics, and comorbidity 12 . This could be explained by different criteria for ICU admission in different countries, and prevalent use of NIV in our cohort on non-ICU floors.

Data reported by the American public media (APM) research labs suggests a large disparity in mortality among African-Americans in Michigan, with 45% of deaths occurring in African-Americans who constitute only 17% of Michigan's

This article is protected by copyright. All rights reserved population 13 . Our cohort demonstrated no significant racial association with mortality among hospitalized patients. In line with multiple studies 7,14-15 , our cohort demonstrates that medical co-morbidity confers a worse prognosis in an incremental fashion. A CCI>3 independently predicted 2.71 increased mortality odds, and patients with CAD/PAD or COPD had 2.86 and 2.23 increased mortality odds, respectively. Additionally, older age is an independent predictor of mortality. Agedependent defects in immune cells leading to a more robust inflammatory response have been suggested as a theory for higher mortality in the elderly 16 .

SARS-CoV-2 utilizes the ACE2 receptor as a site for viral cell entry 17 which is upregulated by ACE-I and NSAIDs. No data exists to date correlating SARS-CoV-2 infection rate with ACE2 levels in vivo. ACE-I/ARB use was associated with no increased mortality or early AKI development in our cohort and has been suggested to have protective effects in other cohorts 18 . This suggests the relative safety of using these agents in individuals at risk of contracting SARS-CoV-2.

Interestingly, NSAID use was correlated with lower mortality odds even when controlling for other predictors in our cohort. Indomethacin has reported in-vivo anti-viral replication properties in SARS-CoV-1 in canines 19 Major limitations in our study include its retrospective design, short follow-up time, and its applicability only to a hospitalized population.

Our study suggests older age and medical comorbidity as independent predictors of in-hospital mortality in COVID-19 patients. NSAID and ACE-I/ARB use prior to hospitalization is not associated with early AKI or increased mortality. Non-steroidal anti-inflammatory medication; ACE-I: angiotensin converting enzyme-inhibitor; ARB: angiotensin receptor blocker; CXR, chest X-ray; CT, computed tomography; aOR: adjusted odds ratio; CI, confidence interval; CAD, coronary artery disease; PAD, peripheral artery disease; CCI, Charlson Comorbidity Index.

COVID-19 Map -Johns Hopkins Coronavirus Resource Center

Rapidly increasing cumulative incidence of coronavirus disease (COVID-19) in the European Union/European Economic Area and the United Kingdom

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Clinical management of severe acute respiratory infection when COVID-19 is suspected

(ncov)-infection-is-suspected

A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation

KDIGO Clinical Practice Guideline for Acute Kidney Injury

Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis

GI symptoms as early signs of COVID-19 in hospitalised Italian patients

Critical Care Utilization for the COVID-19 Outbreak in Lombardy

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

An interpretable mortality prediction model for COVID-19 patients

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in

China: a retrospective cohort study

SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?

Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19

Indomethacin has a potent antiviral activity against SARS coronavirus

This article is protected by copyright. All rights reserved